DJIA 17,279.74 13.75 0.08%
NASDAQ 4,579.79 -13.64 -0.30%
S&P 500 2,010.40 -0.96 -0.05%
market minute promo


company name or ticker
Company Photos
(Click to zoom)

Baxter Will Remain Diversified and With Competitive Advantages

Weekly Pharma Notes: Bristol-Myers Squibb, Pfizer, Merck And Roche

3 Stocks Reiterated As A Buy: BMY, VZ, GILD

Eli Lilly-Boehringer Drug's Cost Effectiveness Questioned - Analyst Blog

Bristol-Myers Squibb Gets European Approval For HCV Drug Daklinza

Bristol-Myers: Absolute Valuation Model versus Relative Valuation Model

Bristol-Myers' Oral HCV Treatment Daklinza Gets EU Clearance - Analyst Blog

Has Gilead Sciences, Inc.'s Star Drug Already Peaked?

Prescriptions of Gilead Sciences' hepatitis C drug Sovaldi peaked, but sales will pick up after the new combination product is approved.

Bristol-Myers Squibb's Daklinza Threatens Johnson & Johnson More Than Gilead Sciences

European approval of Bristol-Myers Squibb's Daklinza could derail sales of Johnson & Johnson's Olysio, but is unlikely to unseat Gilead's Sovaldi.

Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers at Hold

See More Articles...